Nature paper on RGLS4326 | RGLS Message Board Posts

Regulus Therapeutics Inc.

  RGLS website

  • To open or close the box of links at the top of your board, click the "hide/show" button to the right of your page, as shown here:


    To view a vertical list of all your board links on a separate page, click the "View Full List" link in parentheses.

    In the meantime, we will see what we can do to bring more attention to the "hide/show" button, such as making it bigger and/or adding color to it.

    Please continue sending constructive feedback via PM to Admin or email admin@investorvillage.com. We appreciate hearing from you!

RGLS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  561 of 603  at  9/20/2019 8:35:06 AM  by

Dendrimer


Nature paper on RGLS4326

 

Regulus have published their preclinical work on RGLS4326 for ADPKD in Nature. There’s no mention that I could see of the mouse tox that led to the clinical hold. I was interested to note that RGLS4326 uses a mixture of cEt, 2’-F and 2’O-Me modifications.

 

https://www.nature.com/articles/s41467-019-11918-y#Fig6

 

One interesting aspect is the preferential distribution of RGLS4326 to the kidney (8 to 13x the exposure in liver) which I think is unusual for an oligo. If they can figure out why, this would enable a unique kidney targeting capability.

 

I’ve pasted the discussion section below and highlighted the passage that affirms what got me interested in Regulus in the first place - the potential to normalise gene expression in complex diseases.

 

 

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 54
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...